Company: LCTX
Filing Date: 2025-03-10
Form Type: 10-K
Source: 0000950170-25-036309
Chunk: 186

Company: Lineage Cell Therapeutics, Inc.
Filing Date: 2025-03-10
Form: 10-K
Item: Item 1B
Chunk 186
---
805, Business Combinations.(4)The acquired patents and acquired royalty contracts were fully amortized as of the end of the first quarter of 2024.Lineage recognized $22,000 and $130,000 in amortization expense of intangible assets during each of the years ended December 31, 2024 and 2023, respectively. 

116

7. Accounts Payable and Accrued LiabilitiesAt December 31, 2024 and 2023, accounts payable and accrued liabilities consist of the following (in thousands): 

        December 31, 2024

        December 31, 2023

        Accounts payable
         
        $
        1,174

        $
        2,050

        Accrued compensation

        3,066

        3,123

        Accrued liabilities

        1,197

        1,097

        Total
         
        $
        5,437

        $
        6,270

8. Fair Value MeasurementsFair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. To increase the comparability of fair value measures, the following hierarchy prioritizes the inputs to valuation methodologies used to measure fair value in accordance with (ASC 820-10-50), Fair Value Measurements and Disclosures:•Level 1 – Inputs to the valuation methodology are quoted prices for identical assets or liabilities in active markets. •Level 2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. •Level 3 – Inputs to the valuation methodology that are unobservable. Unobservable inputs are those in which little or no market data exists, reflect those that a market participant would use, and are therefore determined using estimates and assumptions developed by the Company.  We have not transferred any instruments between the three levels of the fair value hierarchy.The carrying value of cash, restricted cash, accounts receivable, accounts payable, and accrued liabilities approximate their respective fair values due to their relative short maturities. We measure our cash equivalents, marketable securities and our liability classified warrants at fair value on a recurring basis. The fair values of such assets and liabilities were as follows